Literature DB >> 3690545

Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study.

R E Slayton1, J A Blessing, C Angel, M Berman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3690545

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  9 in total

1.  A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.

Authors:  H J Mackay; R J Buckanovich; H Hirte; R Correa; P Hoskins; J Biagi; L P Martin; G F Fleming; R Morgan; L Wang; R Polintan; A M Oza
Journal:  Gynecol Oncol       Date:  2011-12-02       Impact factor: 5.482

2.  A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.

Authors:  Linda R Duska; John A Blessing; Jacob Rotmensch; Robert S Mannel; Parviz Hanjani; Peter G Rose; Don S Dizon
Journal:  Gynecol Oncol       Date:  2014-08-01       Impact factor: 5.482

3.  Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma.

Authors:  R E Hawkins; E Wiltshaw; J L Mansi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

Authors:  Martee L Hensley; John A Blessing; Robert Mannel; Peter G Rose
Journal:  Gynecol Oncol       Date:  2008-06       Impact factor: 5.482

5.  Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

Authors:  Martee L Hensley; Michael W Sill; Dennis R Scribner; Jubilee Brown; Robert L Debernardo; Ellen M Hartenbach; Carolyn K McCourt; James R Bosscher; Paola A Gehrig
Journal:  Gynecol Oncol       Date:  2009-10-06       Impact factor: 5.482

6.  A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma.

Authors:  Wataru Yamagami; Nobuyuki Susumu; Tomomi Ninomiya; Michiko Kuwahata; Aya Takigawa; Hiroyuki Nomura; Fumio Kataoka; Eiichiro Tominaga; Kouji Banno; Hiroshi Tsuda; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2014-03-31

7.  Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

Authors:  Martee L Hensley; John A Blessing; Koen Degeest; Ovadia Abulafia; Peter G Rose; Howard D Homesley
Journal:  Gynecol Oncol       Date:  2008-04-18       Impact factor: 5.482

Review 8.  The role of adjuvant therapy in uterine leiomyosarcoma.

Authors:  Jennifer A Ducie; Mario M Leitao
Journal:  Expert Rev Anticancer Ther       Date:  2015-11-26       Impact factor: 4.512

9.  Locally-advanced unresected uterine leiomyosarcoma with triple-modality treatment combining radiotherapy, chemotherapy and hyperthermia: A case report.

Authors:  Aya Shirafuji; Akiko Shinagawa; Tetsuji Kurokawa; Yoshio Yoshida
Journal:  Oncol Lett       Date:  2014-05-28       Impact factor: 2.967
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.